10 May 2022 : Original article
Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study
Bruno Roche1BCDE, Artur Bauhofer2ACDEF*, Miguel Ãngel Gomez Bravo3BCDE, Georges Philippe Pageaux4ABCDE, Fabien Zoulim5BDE, Alejandra Otero6BC, Martin Prieto78BC, Carmen Baliellas9BC, Didier Samuel1ACDEDOI: 10.12659/AOT.936162
Ann Transplant 2022; 27:e936162
Table 1 Demographic characteristics and relevant medical history data.
| Full analysis set (N=195) | |
|---|---|
| 59.0 (19, 81) | |
| , * | 74.0 (43, 129) |
| Male | 160 (82.1) |
| Female | 35 (17.9) |
| 16.6 (±9.0) | |
| 14 (7.2) | |
| HBV-induced liver cirrhosis | 100 (51.3) |
| HCC | 83 (42.6) |
| HBV-induced fulminant hepatitis | 12 (6.2) |
| Whole liver | 179 (91.8) |
| Split liver, deceased donor liver transplant | 8 (4.1) |
| Living donor liver transplant | 5 (2.6) |
| Liver and kidney co-transplant | 3 (1.5) |
| 91 (46.7) | |
| 106 (54.5) | |
| Alcoholic liver disease | 39 (20.0) |
| Non-alcoholic steatohepatitis | 7 (3.6) |
| Autoimmune hepatitis | 2 (1.0) |
| Primary sclerosing cholangitis | 2 (1.0) |
| Other | 6 (3.1) |
| Arterial hypertension | 38 (19.5) |
| Diabetes mellitus | 34 (17.4) |
| Kidney disease | 26 (13.3) |
| Allergy | 10 (5.1) |
| Cancer** | 3 (1.5) |
| Hepatitis D virus | 43 (22.1) |
| Hepatitis C virus | 19 (9.7) |
| Human immunodeficiency virus | 7 (3.6) |
| * Based on data of 188 patients; ** papillary thyroid carcinoma, prostatic adenocarcinoma, kidney carcinoma. HBV – hepatitis B virus; HCC – hepatocellular carcinoma; LT – liver transplantation; SD – standard deviation. | |